For the thousands of adults entering kidney transplant evaluation each year, the underlying cause of their kidney failure often remains a diagnostic guess — and that uncertainty has real consequences for donor compatibility, disease recurrence risk, and post-transplant management. New evidence suggests that routine genetic screening at the point of transplant candidacy can fundamentally rewrite those diagnoses for a substantial proportion of patients.
In a prospective observational cohort of 270 kidney transplant candidates evaluated between 2021 and 2024, standardized genetic testing returned positive findings in 104 individuals — a 38.5% yield that is strikingly high for a clinical, rather than research, population. The diagnostic impact was sharpest in two groups often considered diagnostically settled: candidates with end-stage kidney disease attributed to hypertension (43.2% positive rate) and those with no known cause (36.4% positive rate). APOL1-mediated kidney disease emerged as the predominant genetic diagnosis, and positive results were more frequent among younger and Black candidates. A family history of kidney disease independently doubled the odds of a positive genetic result, with an adjusted odds ratio of 1.91.
This study's findings challenge a widely held clinical assumption — that hypertension is a sufficient explanation for kidney failure, particularly in Black patients. APOL1 risk variants, carried at elevated frequency in individuals of West African ancestry, are now understood to drive a distinct nephropathy that mimics hypertensive damage on clinical presentation but carries different recurrence and donor-selection implications. The 38.5% positive yield across a general transplant candidate population is notably higher than yields reported in earlier nephrology genetics studies, likely reflecting the broader indications used here. Key limitations include the single-center observational design, the absence of a non-tested control group, and the short follow-up window for post-transplant outcomes. Still, the practical implication is clear: genetic testing at transplant evaluation is not a niche add-on — it is a diagnostic tool with immediate clinical decision points attached.